Physician profile
Sindhu Devarashetty
NPI 1831622737
$7,946.87
in general payments reported to CMS, 2019-2025
42 companies · $3,664 in 2025
The $3,664 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $222 · 2022: $554 · 2023: $665 · 2024: $2,717 · 2025: $3,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,900 · Long Term Medical Supply Or Device Loan: $1,696 · Grant: $350 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,899.94 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Grant | $350.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,165.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $972.18 | 2021-2025 | Lynparza, Calquence, Enhertu |
| Daiichi Sankyo INC. | $762.93 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $345.63 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $337.02 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $279.67 | 2022-2025 | Jemperli, Zejula |
| Abbvie INC. | $278.26 | 2024-2025 | |
| Celgene Corporation | $189.10 | 2024-2025 | Reblozyl, Breyanzi |
| Stemline Therapeutics INC. | $171.04 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $162.65 | 2024-2025 | |
| Incyte Corporation | $159.47 | 2022-2025 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $150.39 | 2023-2025 | Darzalex, Imbruvica, Talvey |
| Eisai INC. | $146.82 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.81 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $129.59 | 2024-2025 | Sylvant |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $125.35 | 2023-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $112.05 | 2023-2024 | Opdivo, Opdualag |
| Apellis Pharmaceuticals, INC. | $108.49 | 2022-2025 | |
| Genentech USA, INC. | $104.50 | 2022-2025 | Itovebi, Tecentriq, Phesgo |
| Gilead Sciences, INC. | $100.43 | 2024-2025 | Trodelvy |
| Global Blood Therapeutics, INC. | $99.62 | 2021-2022 | |
| Kite Pharma, INC. | $96.09 | 2021 | |
| Beone Medicines USA, INC. | $89.84 | 2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $87.26 | 2024-2025 | Tivdak, Epkinly |
| Astellas Pharma US INC | $75.68 | 2024-2025 | Vyloy, Xtandi |
| Alexion Pharmaceuticals, INC. | $72.23 | 2022-2025 | Ultomiris |
| Seagen INC. | $62.09 | 2021-2023 | Adcetris, Tukysa |
| Tempus Ai, INC | $56.70 | 2024-2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $49.78 | 2025 | Iclusig, Ninlaro |
| Emd Serono, INC. | $48.98 | 2024-2025 | |
| Adc Therapeutics America, INC. | $40.02 | 2024 | |
| Tersera Therapeutics LLC | $32.96 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $23.87 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.78 | 2024 | Libtayo |
| Geron Corporation | $21.42 | 2025 | Rytelo |
| Sobi, INC | $21.38 | 2023 | |
| Servier Pharmaceuticals LLC | $20.51 | 2024 | |
| Pharmaessentia USA Corporation | $18.64 | 2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $18.62 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $18.34 | 2025 | Monoferric |
| Genzyme Corporation | $18.01 | 2022 | |
| Rigel Pharmaceuticals, INC. | $17.77 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Devarashetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.